Source: Annual Congress 2001 - Asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Zech, M. David, M. Seiberling, C. Weimar, T. Bethke, W. Wurst (Konstanz, Freiburg). High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor. Eur Respir J 2001; 16: Suppl. 31, 256

Member's Comments

No comment yet.

Related content which might interest you: Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 42s Year: 2001 Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Comparison of roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone dipropionate in asthma control Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002 Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003 Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017 Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001